NCT00887380 2022-11-18
STARS
Trans Tasman Radiation Oncology Group
Phase 3 Unknown
Clinical Trials
8 trialsNCT05439499 2022-07-06
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03966898 2021-06-02
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT00541086 2020-02-07
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Gruppo Italiano Mammella (GIM)
Phase 3 Unknown
NCT02097459 2016-05-25
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT01402193 2014-06-25
Study of Arimidex and Radiotherapy Sequencing
Fudan University
Phase 3 Unknown
NCT00688194 2013-08-26
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00902954 2009-05-15
LEANEX
Fudan University
Phase 3 Unknown